Logo image of BRNS

BARINTHUS BIOTHERAPEUTICS PL (BRNS) Stock Fundamental Analysis

NASDAQ:BRNS - Nasdaq - US91864C1071 - ADR - Currency: USD

1.1  +0.1 (+10%)

Fundamental Rating

3

Taking everything into account, BRNS scores 3 out of 10 in our fundamental rating. BRNS was compared to 566 industry peers in the Biotechnology industry. BRNS has a great financial health rating, but its profitability evaluates not so good. BRNS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BRNS has reported negative net income.
BRNS had a negative operating cash flow in the past year.
BRNS had negative earnings in 4 of the past 5 years.
BRNS had a negative operating cash flow in each of the past 5 years.
BRNS Yearly Net Income VS EBIT VS OCF VS FCFBRNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

BRNS has a Return On Assets of -38.09%. This is comparable to the rest of the industry: BRNS outperforms 57.77% of its industry peers.
BRNS has a Return On Equity of -46.97%. This is in the better half of the industry: BRNS outperforms 66.08% of its industry peers.
Industry RankSector Rank
ROA -38.09%
ROE -46.97%
ROIC N/A
ROA(3y)-23.44%
ROA(5y)-24.68%
ROE(3y)-28.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRNS Yearly ROA, ROE, ROICBRNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

BRNS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRNS Yearly Profit, Operating, Gross MarginsBRNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

BRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BRNS has more shares outstanding
Compared to 5 years ago, BRNS has more shares outstanding
BRNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BRNS Yearly Shares OutstandingBRNS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BRNS Yearly Total Debt VS Total AssetsBRNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

BRNS has an Altman-Z score of -1.51. This is a bad value and indicates that BRNS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BRNS (-1.51) is comparable to the rest of the industry.
There is no outstanding debt for BRNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.51
ROIC/WACCN/A
WACC9.28%
BRNS Yearly LT Debt VS Equity VS FCFBRNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 8.03 indicates that BRNS has no problem at all paying its short term obligations.
BRNS has a Current ratio of 8.03. This is in the better half of the industry: BRNS outperforms 74.20% of its industry peers.
A Quick Ratio of 8.03 indicates that BRNS has no problem at all paying its short term obligations.
The Quick ratio of BRNS (8.03) is better than 74.20% of its industry peers.
Industry RankSector Rank
Current Ratio 8.03
Quick Ratio 8.03
BRNS Yearly Current Assets VS Current LiabilitesBRNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

BRNS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.27%, which is quite good.
Looking at the last year, BRNS shows a very strong growth in Revenue. The Revenue has grown by 1766.46%.
The Revenue has been growing by 16.92% on average over the past years. This is quite good.
EPS 1Y (TTM)19.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
Revenue 1Y (TTM)1766.46%
Revenue growth 3Y282.26%
Revenue growth 5Y16.92%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -9.41% on average over the next years.
BRNS is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y11.82%
EPS Next 2Y-5.77%
EPS Next 3Y-9.41%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BRNS Yearly Revenue VS EstimatesBRNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BRNS Yearly EPS VS EstimatesBRNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BRNS. In the last year negative earnings were reported.
Also next year BRNS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRNS Price Earnings VS Forward Price EarningsBRNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRNS Per share dataBRNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

BRNS's earnings are expected to decrease with -9.41% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.77%
EPS Next 3Y-9.41%

More info and screens

0

5. Dividend

5.1 Amount

BRNS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BARINTHUS BIOTHERAPEUTICS PL

NASDAQ:BRNS (4/30/2025, 2:05:26 PM)

1.1

+0.1 (+10%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/bmo
Earnings (Next)05-12 2025-05-12/amc
Inst Owners46.29%
Inst Owner ChangeN/A
Ins Owners13.57%
Ins Owner Change0%
Market Cap44.37M
Analysts84.44
Price Target4.59 (317.27%)
Short Float %0.05%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.3%
Min EPS beat(2)-20.97%
Max EPS beat(2)53.56%
EPS beat(4)2
Avg EPS beat(4)14.63%
Min EPS beat(4)-20.97%
Max EPS beat(4)53.56%
EPS beat(8)5
Avg EPS beat(8)12.14%
EPS beat(12)8
Avg EPS beat(12)48.18%
EPS beat(16)11
Avg EPS beat(16)43.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.62%
PT rev (3m)-37.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)27.17%
EPS NY rev (1m)0%
EPS NY rev (3m)27.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.96
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-1.55
EYN/A
EPS(NY)-1.37
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.37
BVpS3.22
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.09%
ROE -46.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.44%
ROA(5y)-24.68%
ROE(3y)-28.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.38%
Cap/Sales 5.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.03
Quick Ratio 8.03
Altman-Z -1.51
F-Score4
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)85.69%
Cap/Depr(5y)117.11%
Cap/Sales(3y)231.54%
Cap/Sales(5y)225.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
EPS Next Y11.82%
EPS Next 2Y-5.77%
EPS Next 3Y-9.41%
EPS Next 5YN/A
Revenue 1Y (TTM)1766.46%
Revenue growth 3Y282.26%
Revenue growth 5Y16.92%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y33.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.68%
EBIT Next 3Y-15.85%
EBIT Next 5YN/A
FCF growth 1Y47.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.17%
OCF growth 3YN/A
OCF growth 5YN/A